308 related articles for article (PubMed ID: 16335702)
1. [Treatment results of Langerhans cell histiocytosis with LSH II protocol].
Mottl H; Ganevová M; Radvanská J; Chánová M; Smelhaus V; Kodet R; Mrhalová M; Tichý M
Cas Lek Cesk; 2005; 144(11):753-5. PubMed ID: 16335702
[TBL] [Abstract][Full Text] [Related]
2. Langerhans cell histiocytosis of skull: a retrospective study of 18 cases.
Zhang XH; Zhang J; Chen ZH; Sai K; Chen YS; Wang J; Ke C; Guo CC; Chen ZP; Mou YG
Ann Palliat Med; 2017 Apr; 6(2):159-164. PubMed ID: 28061539
[TBL] [Abstract][Full Text] [Related]
3. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.
Gadner H; Heitger A; Grois N; Gatterer-Menz I; Ladisch S
Med Pediatr Oncol; 1994; 23(2):72-80. PubMed ID: 8202045
[TBL] [Abstract][Full Text] [Related]
5. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
7. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine.
Mottl H; Starý J; Chánová M; Nekolná M; Drahokoupilová E; Smelhaus V
Leuk Lymphoma; 2006 Sep; 47(9):1881-4. PubMed ID: 17065001
[TBL] [Abstract][Full Text] [Related]
8. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy.
Imashuku S; Okazaki N'; Nakayama M; Fujita N; Fukuyama T; Koike K; Minato T; Kobayashi R; Morimoto A;
Pediatr Blood Cancer; 2008 Feb; 50(2):308-11. PubMed ID: 17458874
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution.
Kamath S; Arkader A; Jubran RF
J Pediatr Orthop; 2014 Dec; 34(8):825-30. PubMed ID: 25387157
[TBL] [Abstract][Full Text] [Related]
10. Acute leukemia in association with Langerhans cell histiocytosis.
Egeler RM; Neglia JP; Aricò M; Favara BE; Heitger A; Nesbit ME
Med Pediatr Oncol; 1994; 23(2):81-5. PubMed ID: 8202046
[TBL] [Abstract][Full Text] [Related]
11. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.
Rodriguez-Galindo C; Kelly P; Jeng M; Presbury GG; Rieman M; Wang W
Am J Hematol; 2002 Mar; 69(3):179-84. PubMed ID: 11891804
[TBL] [Abstract][Full Text] [Related]
12. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal lesion in adult-onset Langerhans cell histiocytosis.
Matsubara Y; Kobayashi M; Hijikata Y; Ota Y; Hirata Y; Lim LA; Yotsuyanagi H; Tojo A
Int J Clin Oncol; 2020 Nov; 25(11):1945-1950. PubMed ID: 32901339
[TBL] [Abstract][Full Text] [Related]
14. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience.
Derenzini E; Stefoni V; Pellegrini C; Gandolfi L; Broccoli A; Casadei B; Quirini F; Argnani L; Tonialini L; Zinzani PL
BMC Cancer; 2015 Nov; 15():879. PubMed ID: 26552668
[TBL] [Abstract][Full Text] [Related]
15. Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?
Sedky MS; Rahman HA; Moussa E; Taha H; Raafat T; Hassanein O
Indian J Pediatr; 2016 Mar; 83(3):214-9. PubMed ID: 26133729
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
Huang JB; Xue HM; Chen YY; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
[TBL] [Abstract][Full Text] [Related]
17. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of langerhans cell histiocytosis in children].
Bilić E; Bojanić K; Pavlović M; Konja J; Femenić R; Dapić T; Antabak A; Anticević D; Murat-Susić S; Husar K; Potocki K; Rajić L
Lijec Vjesn; 2011; 133(11-12):376-84. PubMed ID: 22329293
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukin-1 receptor antagonist and tumor necrosis factor-alpha are elevated in children with Langerhans cell histiocytosis.
Rosso DA; Ripoli MF; Roy A; Diez RA; Zelazko ME; Braier JL
J Pediatr Hematol Oncol; 2003 Jun; 25(6):480-3. PubMed ID: 12794527
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Langerhans cell histiocytosis in children with etoposide.
Ishii E; Matsuzaki A; Okamura J; Inoue T; Kajiwara M; Uozumi T; Yoshida N; Miyazaki S; Miyake K; Matsumoto T
Am J Clin Oncol; 1992 Dec; 15(6):515-7. PubMed ID: 1449115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
